CLARIX FLO Inhibits DRG Adhesion-Induced Neuropathic Pain Through the CD44-TRPV1 Signaling Pathway.

Area of Science:

• Neuroscience
• Regenerative Medicine
• Pain Research

Background:

• Dorsal root ganglion (DRG) adhesion is a significant factor in failed back surgery syndrome and neuropathic pain.
• Adhesions often result from spinal surgery, disc material leakage, or inflammation, necessitating better models for study.

Purpose of the Study:

• To investigate the therapeutic efficacy of CLARIX FLO, a novel human amniotic membrane and umbilical cord tissue product, in an animal model of DRG adhesion-induced neuropathic pain.
• To elucidate the underlying mechanisms of CLARIX FLO's action in alleviating pain and inflammation.

Main Methods:

• Development of a reliable animal model for DRG adhesion-induced neuropathic pain.
• Administration of CLARIX FLO to the injured DRG and assessment of pain behaviors (mechanical allodynia).
• Histological analysis of DRG tissue, including outer sheath thickening and inflammatory markers.
• Investigation of molecular mechanisms involving CD44, TNF-α, and TRPV1.

Main Results:

• CLARIX FLO significantly attenuated mechanical allodynia and reduced DRG outer sheath thickening.
• Treatment suppressed the inflammatory microenvironment and decreased hypersensitivity of isolectin B4-positive neurons.
• CLARIX FLO inhibited TNF-α and TRPV1 overexpression, with CD44 identified as a key mediator.

Conclusions:

• CLARIX FLO demonstrates significant analgesic and anti-inflammatory effects in a DRG adhesion model.
• The therapeutic mechanism involves modulation of the CD44-TRPV1 pathway, offering a potential treatment for neuropathic pain associated with DRG adhesion.